InnoviCares, Canada’s only free multi-drug manufacturer patient benefit plan, marked their 600,000 member on April 28, 2014, and their participation rates show signs of acceleration through increasing partnerships and widespread patient satisfaction.
“We are extremely pleased with the growth of innoviCares. Since its launch in January 2013, innoviCares has already grown to bring together 18 different drug manufacturers and nearly 100 products covered,” said Steve Nicolle, CEO of STI Technologies Ltd, innoviCares parent company. “By complementing public and private drug plans through greater access to original brand name medications, we are improving health outcomes and adherence rates for many patients, and at no additional cost to them.”
Employers, associations, physicians, and pharmacists have widely embraced the program, and for countless patients innoviCares offers significant financial savings and stability in their healthcare.
STI Technologies Limited was recently visited by Troy Wellington, an innoviCares member from Barrie, Ontario, who stressed the positive impact that the plan has had in his family’s life. “You don’t think that something so small could make such a big, drastic change in a person’s life, but it did. Emotionally stable, mentally stable, physically stable… The financial burden was lifted from my wife’s shoulders for those medications.”
InnoviCares supports a patient’s choice to remain on original brand name medication by paying towards the cost difference between brand and the generic alternative.
“Reaching out for medical assistance when a person has reasons to believe they may be experiencing mental health concerns is extremely important,” says Dave Gallson, Associate National Executive Director for Moods Disorders Society of Canada. “Working with your Doctor or healthcare professional, proper diagnosis and a care plan which often includes finding the appropriate medication can make a significant impact in a patient’s continued health and well-being. Thanks to innoviCares, patients have access to brand medication at the same price of a generic.”